Licensing deals and spinouts
Our discovery work is focused on defining mechanisms of disease and how we can use this knowledge to develop new diagnostics or therapeutic interventions.
We utilise state-of-the-art technologies at the MRC Weatherall Institute of Molecular Medicine to understand the processes taking place within skin tissue, as we have found this to be an effective approach to drive translational outcomes. This results in much successful licensing activity on such diagnostics and potential drug candidates which are then taken forward by industry partners for next steps towards patient benefit.
Some of the translational activities are more appropriate to take forward through spinouts, where we attract significant external funding built around our patented technologies and know-how.
T-Cypher Bio
One example is T-Cypher Bio which recently licensed our technology platform to discover the target 'antigens' recognised by T cells, immune cells important for skin inflammation and cancer. T-Cypher Bio aims to utilise the approaches to develop new approaches to treat patients and has recently raised substantial Series A funds to take the discoveries to first-in-human studies.